ArticleFrontiers in immunology2024
Regulation of human Th9 cell differentiation by lipid modulators targeting PPAR-γ and acetyl-CoA-carboxylase 1.
Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- PPARγ Signaling in the Central Nervous System: A Review of the Implications in Synaptic Plasticity, Neuroinflammatory and Neoplastic Processes.Neurochemical research · 2026Review
- Pan-tissue transcriptomic profiling of dairy cattle.Journal of animal science and biotechnology · 2026Article
- Combining single cell and bulk transcriptomics with Mendelian randomization identifies gut microbiota related prognostic genes and mechanisms in thyroid cancer.Discover oncology · 2026Article
- Metabolic reprogramming of Th17/Treg imbalance in autoimmune thyroid diseases.Cell communication and signaling : CCS · 2026Review
- Stearoyl-CoA desaturase-1 controls the differentiation and antitumoral function of Th9 lymphocytes.Journal for immunotherapy of cancer · 2026Article
- Cellular metabolism in Th9, Th17, and Treg cell differentiation.International immunology · 2025Review
- The Pathogenic Role of T Cell Metabolism and its Effect on Immune Senescence in Autoimmune Diseases and Infection.Clinical reviews in allergy & immunology · 2025Review
- Targeting Th9 cells in autoimmune diseases: a narrative review.Frontiers in immunology · 2025Review
- Emerging Role and Function of Th9 Cells in Allergic Inflammation.Journal of inflammation research · 2025Review
- Oxidative stress-related genes in uveal melanoma: the role of CALM1 in modulating oxidative stress and apoptosis and its prognostic significance.Frontiers in oncology · 2025Article
- Regulatory mechanisms of Th9 cell differentiation.Frontiers in immunology · 2025Review
- Metabolic regulation of Th9 cell differentiation: insights for IL-9-driven diseases.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD4 T cell activation induces dramatic changes to cellular metabolism for supporting their growth and differentiation into effector subsets. While the cytokines IL-4, TGF-β and IL-21 promote differentiation into Th9 cells, metabolic factors regulating this process remain poorly understood. To assess the role of lipid metabolism in human Th9 cell differentiation, naïve CD4 T cells were purified from blood of healthy volunteers and cultured in the presence or absence of compounds targeting PPAR-γ, acetyl-CoA-carboxylase 1 (ACC1), and AMP-activated protein kinase (AMPK) for four days. Th9 cell differentiation significantly increased PPARG expression, and the PPAR-γ agonist rosiglitazone suppressed IL-9 in a dose-dependent manner. The rosiglitazone-mediated suppression also occurred in the presence of the glucose metabolism inhibitor 2-deoxy-D-glucose, suggesting it was independent of glycolysis. On the other hand, the PPAR-γ antagonist GW9662 had no significant effect on IL-9 production. Next, the role of fatty acid synthesis was tested by treating cells with inhibitors of ACC1 (TOFA) or AMP-activated protein kinase (AMPK; dorsomorphin). We demonstrate reciprocal functions for these enzymes, as ACC1 inhibition substantially increased IL-9 production, whereas AMPK inhibition resulted in undetectable levels. TOFA also decreased expression of ACACA, the gene encoding ACC1, demonstrating regulation at the transcriptional level. Finally, combining TOFA treatment with exogenous oleic acid restored IL-9 back to the levels in control Th9 cultures, suggesting that ACC1 suppresses Th9 differentiation through fatty acid synthesis. Overall, our data demonstrate that lipid regulators associated with intracellular fatty acid accumulation suppress Th9 cell differentiation. These findings may have clinical implications for conditions associated with elevated IL-9 production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.